Uncategorized - Maus Lab

WHAT’S NEW WITH THE CAR-TOLOGISTS?

THE MAUS LAB 411∙ BB

The Maus Lab and the Cellular Immunotherapy Program (CIP) have had a productive year! We published 3 primary research articles, including articles in Science Translational Medicine on CARs that can be turned ON or OFF, in Molecular Therapy on how the signaling within T cells change when CARs use different co-stimulatory domains, and the Journal of Immunotherapy for Cancer on using artificial antigen presenting cells to manufacture more cost-effective CAR T cells. We also published 5 reviews and 2 clinical perspectives. Marcela also contributed to 18 additional articles! We’re excited to share that we submitted a record 8 abstracts to the American Society of Hematology annual meeting, to be held virtually and in Atlanta, GA in December, and 4 were selected for oral presentations and 4 for posters. Congratulations to all — this is an amazing accomplishment! Read on to find out more about what we’ve been up to and our achievements this year.

IMMUNO-ONCOLOGY 360° Autumn 2021 Newsletter

In this newsletter, we are pleased to share brief, but in-depth interviews with IO leadership and the work they are advancing in immuno-resistance and rational combinations, strategies to expand the CAR-T cell therapeutic window, next-generation engineered T-cell therapies, recent developments in the field of T-cell exhaustion, ongoing CAR-T cell therapy clinical trials for brain cancers, managing through the pandemic and new research to better understand and develop cell therapies…

POTENTIATING NOVEL ENGINEERED CELLULAR THERAPIES FOR SOLID TUMORS

In preliminary data from the first-in-human clinical trial of CART-EGFRvIII in patients with recurrent GBM expressing EGFRvIII, Dr. Maus’ group found that infusion of CART-EGFRvIII cells is safe, without evidence of off-tumor toxicity such as cross-reactivity to wild type EGFR. Although they observed trafficking of CAR T cells into the…

SU2C’S RESEARCH IN THE FIGHT AGAINST GLIOBLASTOMA

Glioblastoma multiforme (GBM), a devastating type of brain cancer, has been in the news again with Senator John McCain’s recent diagnosis. It is notoriously aggressive, growing rapidly and often defying treatment with surgery, radiation and chemotherapy. Tumors can be removed by surgery, but they nearly always come back. By most estimates, half the patients with this diagnosis will succumb to it in 15 to 18 months, and only five or 10 percent will be living in…

The Next Cancer Breakthroughs

An inside look at five research developments that have the potential to transform the treatment of cancer

“Cancer treatment is evolving rapidly. New techniques can identify and target tumor vulnerabilities while leaving healthy cells alone. Immunotherapy can harness the body’s immune system to fight cancer. But new treatments still don’t work for everyone. We need more breakthroughs.”